Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Clinical Trials: Overview01:11

Clinical Trials: Overview

3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Clinical Trials01:16

Clinical Trials

7.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
7.8K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Post Hoc Subgroup and Body Region Analyses of VASI Outcomes Among Patients with Vitiligo in a Phase 2 Povorcitinib Trial.

Advances in therapy·2026
Same author

Author Correction: Atopic dermatitis.

Nature reviews. Disease primers·2026
Same author

Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary.

The Journal of dermatological treatment·2026
Same author

Atopic dermatitis.

Nature reviews. Disease primers·2026
Same author

Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial.

The Journal of dermatological treatment·2026
Same author

Repeated switching between biosimilar ABP 654 and reference ustekinumab in patients with moderate-to-severe plaque psoriasis: a randomized, double-blinded clinical trial to support interchangeability.

The British journal of dermatology·2026

相关实验视频

Updated: Sep 9, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.2K

在中度至重度的阿托皮炎患者中使用upadacitinib的有效性和安全性:通过140周的第三阶段随机临床试验结果

Alan D Irvine1, Vimal H Prajapati2,3,4,5,6,7, Emma Guttman-Yassky8

  • 1Clinical Medicine, Trinity College Dublin, Dermatology, Children's Health Ireland at Crumlin, Dublin 12, Ireland. irvinea@tcd.ie.

American journal of clinical dermatology
|September 3, 2025
PubMed
概括

在成人和青少年中,长期治疗 (长达140周) 显示出持续的疗效和有利的安全性. 这项研究提供了关于upadacitinib治疗阿尔茨海默病的关键数据.

更多相关视频

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

9.8K
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.3K

相关实验视频

Last Updated: Sep 9, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.2K
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

9.8K
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.3K

科学领域:

  • 皮肤病学
  • 免疫学
  • 药理学

背景情况:

  • 乌帕达西尼布是一种口服选择性Janus激酶抑制剂,用于中度至重度的亚托皮炎 (AD).
  • 需要超过一年的长期疗效和安全性数据.

研究的目的:

  • 在中度至重度AD的成年和青少年患者中评估upadacitinib治疗的长期疗效和安全性.

主要方法:

  • 在3期随机临床试验中 (Measure Up 1, Measure Up 2, AD Up) 评估了15毫克和30毫克的上巴西替尼.
  • 通过湿疹区域和严重性指数 (EASI),验证的研究人员全球评估 (vIGA- AD) 和最坏的数值评分表 (WP- NRS) 评估有效性.
  • 通过治疗出现的不良事件来评估安全性.

主要成果:

  • 疗效反应率,包括EASI 90和WP-NRS 0/ 1,持续了140周.
  • 在第140周,EASI 75在81. 5% - 90. 5%的患者和vIGA- AD 0/1在52. 0% - 64. 4%的患者中实现.
  • 在第140周,超过60%的患者获得了临床显著的缩 (∆WP-NRS≥4).

结论:

  • 乌帕达西尼布 (UPA15和UPA30) 显示出强大而持久的疗效,长达140周.
  • 在长期治疗期间,安全性保持一致和有利.
  • 在成人和青少年中,upadacitinib 是一种可行的长期治疗选择.